Recent studies have shown that for patients receiving both EGFR-TKI and radiotherapy, overlapping treatment duration is an independent risk factor for radiation pneumonitis, suggesting that reducing overlap time can decrease the incidence of radiation pneumonitis (40). The gene discussed is EGFR; the disease is radiation pneumonitis.